Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhejiang University
Approximately 450 diabetic and 450 obese patients will be enrolled from Lanxi in China. They will be randomly assigned into one of the following three groups: Omega-3 fatty acids capsules (1.5 g/d); or omega-3 fatty acids capsules (3 g/d); or placebo capsules. Blood, feces and urine samples will be collected before and after treatment. Glucose and lipid parameters will be measured. Diabetes comorbidities and complications will also be assessed. This study will also explore the new mechanisms of n-3 PUFAs on improving glucose and lipid homeostasis and other outcomes based on multi-omics and establish a model for precision intervention.
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed type 2 diabetes for diabetic groups according to WHO diagnostic criteria;
BMI≥28 for obese groups;
Aged between 40 and 75 years.
You may not be if
Type 1 diabetes;
Cardiovascular disease;
Cancer;
Liver or kidney disease;
Premenopausal women, pregnancy or lactation;
Allergy to fish;
Have participated in other clinical trials in the last three months.
Clareo Health | The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients
